Innate Pharma SA (FR:IPH) has released an update.
Innate Pharma SA, a clinical-stage biotechnology company, announced its total number of shares and voting rights as of June 10, 2024, revealing 80,967,407 ordinary shares and a mix of preferred shares alongside 81,724,597 theoretical and 81,706,022 exercisable voting rights. The company specializes in developing immunotherapies for cancer patients, leveraging its proprietary ANKET platform and collaborating with industry leaders such as Sanofi and AstraZeneca. Innate Pharma emphasizes its innovative approach in harnessing the innate immune system to benefit cancer patients worldwide.
For further insights into FR:IPH stock, check out TipRanks’ Stock Analysis page.
